Dr. Chloé Dubois

Pathologist · Osaka University Hospital · Japan (JP) · Oncology

Tier 3STK-0061GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC
Scientific interests: irAE managementBrain metastases
Engagement preference: In person
Advisory boards: 0
Publications: 1
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 15 Feb 2026 (212 days ago)
Next planned contact: 15 Feb 2027
Last 6 months vs target: 0%
0 of 1 expected engagements

Insights from this stakeholder (0)

No insights captured from engagements with this stakeholder.

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
15 Feb 2026	Scientific exchange	Phone	James Whitfield	Vantrexa	Duration of responseElderly / ECOG 2 patients+1	0	—	Reviewed	ENG-0061

Timeline

15 Feb 2026
Scientific exchange
Duration of response, Elderly / ECOG 2 patients, Infusion-reaction management

Related stakeholders (9)

Osaka University Hospital

Dr. Javier Weber
Pathologist
Tier 3
Dr. Noor Dubois
Thoracic medical oncologist
Tier 3
Dr. Yuki Quinn
Thoracic medical oncologist
Tier 2
Dr. Tomoko Ueda
Pathologist
Tier 2
Dr. Ximena Rossi
Radiation oncologist
Tier 1
Dr. Benedikt Ivanova
Oncology pharmacist
Tier 2
Dr. Farah Jensen
Primary care physician
Tier 1
Dr. Ximena Bauer
General neurologist
Tier 3
Dr. Andrea Fischer
General neurologist
Tier 2